Bicalutamide是一种口服有效的非甾体雄激素受体（AR）拮抗剂,可用于前列腺癌研究。
|
英文别名 (English Synonym) |
Bicalutamide |
|
中文名称 (Chinese Name) |
比卡鲁胺 |
|
靶点 (Target) |
Androgen Receptor |
|
通路 (Pathway) |
Endocrinology and Hormones |
|
CAS号 (CAS NO.) |
90357-06-5 |
|
分子式 (Formula) |
C18H14F4N2O4S |
|
分子量 (Molecular Weight) |
430.37 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15,72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. PMID: 22266222, PMCID: PMC3306502.
